Holen Sie sich die Stockscreener-App
11.23
5.14%
0.52
Schlusskurs vom Vortag:
$10.71
Offen:
$11.01
24-Stunden-Volumen:
311.32K
Relative Volume:
0.77
Marktkapitalisierung:
$608.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-2.5061
EPS:
-4.481
Netto-Cashflow:
-
1W Leistung:
-1.05%
1M Leistung:
+21.21%
6M Leistung:
-24.48%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.86
$11.47
1-Wochen-Bereich:
$10.61
$11.66
52-Wochen-Spanne:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Firmenname
Eikon Therapeutics Inc
Sektor
Branche
Telefon
341-777-0566
Adresse
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
11.24 | 580.11M | 0 | 0 | 0 | -4.481 |
VRTX
Vertex Pharmaceuticals Inc
|
521.28 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.12 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.36 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.10 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | BofA Securities | Buy |
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-02 | Eingeleitet | Mizuho | Outperform |
| 2026-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-02-26 | Eingeleitet | Wedbush | Underperform |
Alle ansehen
Eikon Therapeutics Inc Aktie (EIKN) Neueste Nachrichten
Eikon Therapeutics (NASDAQ:EIKN) Trading Up 6.9% After Insider Buying Activity - MarketBeat
Eikon Therapeutics (NASDAQ:EIKN) Raised to Strong-Buy at Mizuho - MarketBeat
Group Iv Gp Lp Column Buys 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock - MarketBeat
Open-market insider buy at Eikon Therapeutics (EIKN) - Stock Titan
Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com - Investing.com South Africa
A Bristol Myers Squibb research leader joins Eikon as science chief - Stock Titan
BlackRock Inc. Buys 962,046 Shares of Eikon Therapeutics, Inc. $EIKN - MarketBeat
EDGAR Filing Documents for 0001193125-26-349936 - sec.gov
Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Moomoo
Eikon (EIKN) Financial Update: EPS Misses Its Estimate on the Day; After Results: The Stock Ends Up 12.46% in the Latest SessionProfit Announcement - vinanet.vn
Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 - finance.yahoo.com
Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com
Eikon Therapeutics adds Merck chemistry head to advisory board By Investing.com - Investing.com Nigeria
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald - Sahm
An oncology expert will discuss PARP drugs in four cancers Aug. 20 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
EIKN Q1 2026 Earnings: Deeper-than-Expected Loss but Shares Rally 6.97%Energy Earnings Report - vinanet.vn
$Eikon Therapeutics (EIKN.US)$ - Moomoo
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Australia
Eikon Therapeutics Updates Corporate Presentation, Files Form 8-K Under Regulation FD - kalkinemedia.com
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside - TradingView
Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k - simplywall.st
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee - marketscreener.com
Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary - TradingView
Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash - Stock Titan
Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - Yahoo Finance
FMR LLC Expands Eikon Therapeutics Inc (EIKN) Stake Despite Post-IPO Slide - GuruFocus
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma - The Manila Times
Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced Melanoma - marketscreener.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. To Its Scientific Advisory Board - TradingView
Eikon Therapeutics adds Merck chemistry head to advisory board - Investing.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board - The Manila Times
Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board - Moomoo
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G - Stock Titan
Certain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.com
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock Titan
Eikon Therapeutics (EIKN) Holds Near $9.15 as Shares Consolidate Above Key SupportStock Analysis - vinanet.vn
S.F. heart drug developer Braveheart Bio poised for 2nd-largest biotech IPO this year - The Business Journals
Eikon Therapeutics : Company Presentation - marketscreener.com
Eikon Therapeutics, Inc.'s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th - MarketBeat
Eikon Therapeutics Shares Up on First Dose to Patient in Phase 2/3 Lung Cancer Trial - Moomoo
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Eikon Therapeutics doses first patient in lung cancer trial - Investing.com
Eikon Therapeutics Doses First Patient in Phase 2/3 Trial for EIK1001 in Non-Small Cell Lung Cancer - marketscreener.com
Eikon Therapeutics doses first patient in lung cancer trial By Investing.com - Investing.com Canada
Eikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLC - Quiver Quantitative
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer - GlobeNewswire
Finanzdaten der Eikon Therapeutics Inc-Aktie (EIKN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eikon Therapeutics Inc-Aktie (EIKN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Column Group IV GP, LP | 10% Owner |
Feb 06 '26 |
Buy |
18.00 |
2,117,760 |
38,119,680 |
4,312,139 |
| Foresite Capital Management IV | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
55,555 |
999,990 |
1,318,983 |
| FRAZIER KENNETH C | Director |
Feb 04 '26 |
Buy |
18.00 |
111,111 |
1,999,998 |
111,111 |
| Wolfe Josh | Director |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
| Lux Venture Partners V, LLC | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):